Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05569252 · ClinicalTrials.gov registry record · Phase 2
A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum
A Phase 2 study of Pseudoxanthoma Elasticum, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
- 7
- Study locations
NCT05569252 is a Phase 2 study of Pseudoxanthoma Elasticum that has completed, run by Daiichi Sankyo. The registered enrollment target is 65 participants, below the 135-participant average among 3 other Pseudoxanthoma Elasticum trials with a reported enrollment target (52% lower). The trial reports 7 study locations across 6 states.
The verdict
NCT05569252, a Phase 2 study of Pseudoxanthoma Elasticum, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study was designed to evaluate the safety, tolerability, pharmacodynamics (PD) of DS-1211b, and pharmacokinetics (PK) in individuals with Pseudoxanthoma elasticum (PXE). PXE is a rare disease that is associated with significant risks of visual impairments and comorbidity from peripheral and cardiovascular diseases, and adversely impacts the quality of life in afflicted individuals.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG DS-1211b
Study Locations (7)
Massachusetts
- Boston Neuro Research Center - North Dartmouth
- Infinity Medical Research Inc - North Dartmouth
Maryland
- Mid-Atlantic Epilepsy and Sleep Center - Bethesda
New Jersey
- Frontage Clinical Services, Inc. - Secaucus
New York
- Clinilabs - New York
Pennsylvania
- Clinical Research of Philadelphia, LLC - Philadelphia
Other
- UMC Utrecht - Utrecht
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2022-10-20 |
| Est. Completion | 2023-11-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05569252
The ClinicalTrials.gov registry entry for NCT05569252 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 135-participant average among 3 other Pseudoxanthoma Elasticum trials with a reported enrollment target (52% lower). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pseudoxanthoma Elasticum appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05569252 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Massachusetts, Maryland, New Jersey.
Frequently Asked Questions
What is clinical trial NCT05569252 about?
NCT05569252 is a clinical study titled "A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum". This study was designed to evaluate the safety, tolerability, pharmacodynamics (PD) of DS-1211b, and pharmacokinetics (PK) in individuals with Pseudoxanthoma elasticum (PXE). PXE is a rare disease that is associated with significant risks of visual impairments and comorbidity from peripheral and car...
What is the current status of trial NCT05569252?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2022-10-20. Estimated completion is 2023-11-21.
What conditions does trial NCT05569252 study?
This clinical trial studies the following conditions: Pseudoxanthoma Elasticum.
What interventions are being tested in trial NCT05569252?
The interventions under investigation include: Placebo (OTHER), DS-1211b (DRUG).
Who is sponsoring clinical trial NCT05569252?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05569252 being conducted?
This trial has 7 study locations across Maryland, Massachusetts, New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pseudoxanthoma Elasticum
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency
RECRUITING · Phase 2
-
The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency
RECRUITING · Phase 1
-
Genetic Analysis of Patients With Pseudoxanthoma Elasticum
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.